公开(公告)号：US20080125389A1

公开(公告)日：2008-05-29

申请号：US11800272

申请日：2007-05-03

Applicant: Pamela L. Paris ,  Colin C. Collins

Inventor： Pamela L. Paris ,  Colin C. Collins

IPC: A61K31/70 ,  C12Q1/68 ,  G01N33/574 ,  A61P43/00 ,  C12Q1/02

CPC classification number: G01N33/57415 ,  C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/136 ,  G01N33/5011 ,  G01N33/57434

Abstract: The present invention provides genomic markers for determining the presence or absence of breast cancer. The invention further demonstrates that inhibition of MEN1 reduces breast or prostate cancer proliferation, thereby demonstrating that inhibition of MEN1 activity or expression can be used to reduce breast cancer or prostate cancer proliferation in an individual in need thereof.

Abstract translation: 本发明提供用于确定乳腺癌存在或不存在的基因组标记。 本发明进一步表明，MEN1的抑制降低了乳腺或前列腺癌的增殖，从而证明了MEN1活性或表达的抑制可用于减少有需要的个体中的乳腺癌或前列腺癌的增殖。

公开(公告)号：US09790500B2

公开(公告)日：2017-10-17

申请号：US15211857

申请日：2016-07-15

Applicant: Yuzhuo Wang ,  Hui Xue ,  Sze Ue Luk ,  Peter Wilhelm Gout ,  Martin E. Gleave ,  Colin C. Collins

Inventor： Yuzhuo Wang ,  Hui Xue ,  Sze Ue Luk ,  Peter Wilhelm Gout ,  Martin E. Gleave ,  Colin C. Collins

IPC: C12N15/11 ,  C12N15/113 ,  A61K31/7125

CPC classification number: C12N15/113 ,  A61K31/7125 ,  C12N2310/11 ,  C12N2310/3125 ,  C12N2310/3145 ,  C12N2310/315 ,  C12N2310/3181 ,  C12N2310/3233 ,  C12N2310/3341 ,  C12N2310/3519 ,  C12N2310/51 ,  C12N2310/321 ,  C12N2310/3525 ,  C12N2310/3527

Abstract: Provided herein are compositions, method and uses for modulating IAP activity or for the treatment of cancer. The compositions comprise dual-targeting antisense oligonucleotides (dASO) for administration to a cancer cell, wherein the cancer cell may be characterized by elevated expression of one of more of BIRC6, cIAP1 or survivin. The cancer may be selected from one or more of: prostate cancer; childhood de novo acute myeloid leukemia; colorectal cancer; neuroblastoma; melanoma; and non-small cell lung cancer. The prostate cancer may be castration-resistant prostate cancer (CRPC).

公开(公告)号：US07482123B2

公开(公告)日：2009-01-27

申请号：US11267461

申请日：2005-11-04

Applicant: Pamela L. Paris ,  Colin C. Collins

Inventor： Pamela L. Paris ,  Colin C. Collins

IPC: C12Q1/68 ,  C07H21/04

CPC classification number: G01N33/5011 ,  C12Q1/6841 ,  C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/136

Abstract: The present invention provides genomic markers for determining the predisposition of prostate cancer to become metastasized.

Abstract translation: 本发明提供用于确定前列腺癌倾向于转移的基因组标记。

公开(公告)号：US20170015997A1

公开(公告)日：2017-01-19

申请号：US15211857

申请日：2016-07-15

Applicant: Yuzhuo Wang ,  Hui Xue ,  Sze Ue Luk ,  Peter Wilhelm Gout ,  Martin E. Gleave ,  Colin C. Collins

Inventor： Yuzhuo Wang ,  Hui Xue ,  Sze Ue Luk ,  Peter Wilhelm Gout ,  Martin E. Gleave ,  Colin C. Collins

IPC: C12N15/113 ,  A61K9/00 ,  A61K9/127 ,  A61K31/7125

CPC classification number: C12N15/113 ,  A61K31/7125 ,  C12N2310/11 ,  C12N2310/3125 ,  C12N2310/3145 ,  C12N2310/315 ,  C12N2310/3181 ,  C12N2310/3233 ,  C12N2310/3341 ,  C12N2310/3519 ,  C12N2310/51 ,  C12N2310/321 ,  C12N2310/3525 ,  C12N2310/3527

Abstract: Provided herein are compositions, method and uses for modulating IAP activity or for the treatment of cancer. The compositions comprise dual-targeting antisense oligonucleotides (dASO) for administration to a cancer cell, wherein the cancer cell may be characterized by elevated expression of one of more of BIRC6, cIAP1 or survivin. The cancer may be selected from one or more of: prostate cancer; childhood de novo acute myeloid leukemia; colorectal cancer; neuroblastoma; melanoma; and non-small cell lung cancer. The prostate cancer may be castration-resistant prostate cancer (CRPC).

Abstract translation: 本文提供了调节IAP活性或治疗癌症的组合物，方法和用途。 所述组合物包含用于给予癌细胞的双靶向反义寡核苷酸（dASO），其中所述癌细胞的特征可能在于BIRC6，cIAP1或存活蛋白中的一种之一升高。 癌症可以选自以下中的一种或多种：前列腺癌; 儿童从头急性骨髓性白血病; 结肠直肠癌; 神经母细胞瘤 黑色素瘤 和非小细胞肺癌。 前列腺癌可能是去势抗性前列腺癌（CRPC）。